VYVGART Hytrulo logo (efgartigimod alfa and hyaluronidase-qvfc) VYVGART Hytrulo logo (efgartigimod alfa and hyaluronidase-qvfc)
A prescription medicine for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
MENU

Questions? Call 1-833-VYV-CIDP (1-833-898-2437)

A prescription medicine for adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
STAY UP TO DATE

Questions? Call 1-833-VYV-CIDP (1-833-898-2437)

Take a look at a CIDP treatment that’s designed differently

VYVGART Hytrulo works differently than treatments like IVIg, SCIg, PLEX, and steroids.

IVIg=intravenous immunoglobulin; PLEX=plasma exchange; SCIg=subcutaneous immunoglobulin.

The first major innovation in CIDP treatment in over 30 years*

The complete cause of CIDP is not fully understood. Recent studies suggest that in some people, harmful antibodies, like harmful IgG antibodies, may be involved in damaging myelin. VYVGART Hytrulo is specifically designed to cause a reduction in the number of IgG antibodies, including harmful IgG antibodies.

*VYVGART Hytrulo contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.
FcRn=neonatal Fc receptor; IgG=immunoglobulin G.

The science behind VYVGART Hytrulo made simple and fun

The science of CIDP can get complex, but this video breaks it down simply. Travel into the body to see how CIDP works and get a better understanding of the science behind VYVGART Hytrulo.

Meet the cast

Your body has many “characters” that influence how information travels between the brain and the rest of your body. Expand below to learn more about some of the possible characters that may play a role in causing CIDP, as well as those that may help treat it with VYVGART Hytrulo.

Helpful IgG antibody

Immunoglobulin G (IgG) antibody is a Y-shaped protein made by the immune system. Antibodies—like IgG—play a vital role in helping protect your body from infection and disease.

Harmful IgG antibody

Harmful IgG antibody is a Y-shaped protein mistakenly made by the immune system that attacks the body. In some people with CIDP, harmful IgG—along with other characters—may be involved in causing damage to the myelin that covers the nerves.

FcRn receptor

Neonatal Fc receptor (FcRn) is a receptor that IgG antibodies attach to. It helps the IgG antibodies stay in the body longer.

Myelin

A protective coating around nerves that helps messages travel efficiently, establishing a two-way line of communication between the brain and the body. Damage to the myelin over time makes it harder for signals to travel quickly along the nerve or can even stop them completely.

VYVGART Hytrulo

VYVGART Hytrulo (shown in purple) contains efgartigimod alfa and hyaluronidase, and is specifically designed to attach to FcRn receptors.

Hyaluronidase

Hyaluronidase is one of the active ingredients in VYVGART Hytrulo that helps to increase the distribution and absorption of ingredients into the body.

MOA MOA MOA

Take a closer look at VYVGART Hytrulo

VYVGART Hytrulo is a fragment of an IgG antibody designed to form a strong bond with FcRn receptors. By keeping some FcRn receptors occupied, more IgG antibodies, including the harmful type, remain unattached and are then destroyed and removed.

Learn more about CIDP and VYVGART Hytrulo from an expert.

VYVGART Hytrulo has 2 active ingredients: efgartigimod alfa and hyaluronidase (human recombinant).

discussion guide image discussion guide image discussion guide image

You’re the main character—make the most of your next conversation

The CIDP Doctor Discussion Guide can help you take note of your CIDP symptoms and abilities. Providing a better understanding of your daily life with CIDP may help your doctor determine if VYVGART Hytrulo is right for you.

GET YOUR GUIDE

Understand more about VYVGART Hytrulo

VYVGART Hytrulo study results

See the safety and effectiveness results from the largest clinical study in CIDP history.

View the results

Self-injection with the VYVGART Hytrulo prefilled syringe

The first and only self-injection for CIDP that takes about 20-30 seconds.†

†Please see Patient Information. Follow appropriate administration steps in the Instructions for Use. Monitor for signs and symptoms of an allergic reaction for at least 30 minutes after injection. If an allergic reaction occurs, you should seek medical attention..

Discover more

Have questions? Call 1-833-VYV-CIDP (1-833-898-2437) to speak with an educator about CIDP, how VYVGART Hytrulo works, study results, cost and coverage, and more.

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • hives
    • trouble breathing
    • low blood pressure
    • fainting
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.

Do not take VYVGART HYTRULO if you are allergic to efgartigimod alfa, hyaluronidase, or any of the ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting.

Before taking VYVGART HYTRULO, tell your healthcare provider about all of your medical conditions, including if you:

  • have an infection or fever.
  • have recently received or are scheduled to receive any vaccinations.
  • have any history of allergic reactions.
  • have kidney (renal) problems.
  • are pregnant or plan to become pregnant. It is not known whether VYVGART HYTRULO will harm your unborn baby.
    • Pregnancy Exposure Registry. There is a pregnancy exposure registry for women who use VYVGART HYTRULO during pregnancy. The purpose of this registry is to collect information about your health and your baby. Your healthcare provider can enroll you in this registry. You may also enroll yourself or get more information about the registry by calling 1-855-272-6524 or going to VYVGARTPregnancy.com
  • are breastfeeding or plan to breastfeed. It is not known if VYVGART HYTRULO passes into your breast milk.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

VYVGART HYTRULO can cause side effects which can be serious, including:

  • Infection. VYVGART HYTRULO may increase the risk of infection. If you have an active infection, your healthcare provider should delay your treatment with VYVGART HYTRULO until your infection is gone. Tell your healthcare provider right away if you get any of the following signs and symptoms of an infection:
    • fever
    • chills
    • frequent and painful urination
    • cough
    • pain and blockage of nasal passages
    • wheezing
    • shortness of breath
    • sore throat
    • excess phlegm
    • nasal discharge
  • Allergic reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions that can be severe. These reactions can happen during, shortly after, or weeks after your VYVGART HYTRULO injection. Tell your healthcare provider or get emergency help right away if you have any of the following symptoms of an allergic reaction:
    • rash
    • swelling of the face, lips, throat, or tongue
    • shortness of breath
    • hives
    • trouble breathing
    • low blood pressure
    • fainting
  • Infusion or injection-related reactions. VYVGART HYTRULO can cause infusion or injection-related reactions. These reactions can happen during or shortly after your VYVGART HYTRULO injection. Tell your healthcare provider if you have any of the following symptoms of an infusion or injection-related reaction:
    • high blood pressure
    • chills
    • shivering
    • chest, stomach, or back pain

The most common side effects of VYVGART HYTRULO include respiratory tract infection, headache, urinary tract infection, and injection site reactions.

These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is VYVGART HYTRULO® (efgartigimod alfa and hyaluronidase-qvfc)?

VYVGART HYTRULO is a prescription medicine used to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP).

It is not known if VYVGART HYTRULO is safe and effective in children.

Please see full Prescribing and Patient Information for VYVGART HYTRULO.

Dosage forms and strengths:

VYVGART Hytrulo is available as a single-dose subcutaneous injection containing: 200 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per prefilled syringe, or 180 mg/mL of efgartigimod alfa and 2,000 U/mL of hyaluronidase per vial.

Questions? Call 1-833-VYV-CIDP
(1-833-898-2437)

This site is intended for patients and caregivers.

Disclaimer | Privacy Policy | Contact Us |

Patient and Prescribing Information
VYVGART Hytrulo Patient Information VYVGART Hytrulo Prescribing Information VYVGART Hytrulo Prefilled Syringe Instructions for Use

VYVGART and VYVGART Hytrulo are registered trademarks of argenx.

LIVE VYVIDLY and THAT’S LIVING VYVIDLY are trademarks of argenx.

For U.S. audiences only.

©2025 argenx 

US-VYV_HYT-24-00514 V2 05/2025

argenx logo